Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
复制标题
DOI：
10.1200/jco.22.00754
复制
发表时间：
2022-07-01
影响因子：
45.3
通讯作者：
Pierce, Lori J.
中科院分区：
文献类型：
--
作者：
Oyer, Randall A.;Hurley, Patricia;Pierce, Lori J.
为了增加公平性、多样性和包容性(EDI)并解决癌症临床试验招募和参与的障碍，研究利益相关者之间的协调一致是必要的。试验参与者的种族和民族多样性是了解可能影响患者对癌症治疗反应的内在和外在因素的关键。这份ASCO和社区癌症中心协会(ACCC)的研究声明为研究界提出了具体的建议和战略，以改善癌症临床试验中的EDI。有六个主要建议：(1)临床试验是高质量癌症护理的一个组成部分，每个癌症患者都应该有机会参与；(2)试验赞助商和研究人员应设计和实施试验，重点是减少障碍和加强EDI，并与现场合作，以增加未被充分代表的人群的参与；(3)试验赞助商、研究人员和地点应与患者、患者倡导团体、社区领袖和团体建立长期合作伙伴关系；(4)任何设计或进行试验的人都应该完成反复的教育、培训和评估，以证明和保持跨文化能力、减轻偏见、有效沟通，以及实现EDI的承诺；(5)研究利益相关者应投资于在试验和研究人员中增加EDI的计划和政策；以及(6)研究利益相关者在报告试验结果、计划和干预措施时，应收集并公布试验参与者种族和民族多样性的汇总数据，以增加EDI。这些建议旨在为研究界提供指导，以提高历来在癌症临床试验中代表性不足的种族和少数民族人群的参与率。ASCO和ACCC将在所有级别上努力推进本出版物中的建议。(C)2022年，美国临床肿瘤学会
A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and participation. Racial and ethnic diversity among trial participants is key to understanding intrinsic and extrinsic factors that may affect patient response to cancer treatments. This ASCO and Association of Community Cancer Centers (ACCC) Research Statement presents specific recommendations and strategies for the research community to improve EDI in cancer clinical trials. There are six overarching recommendations: (1) clinical trials are an integral component of high-quality cancer care, and every person with cancer should have the opportunity to participate; (2) trial sponsors and investigators should design and implement trials with a focus on reducing barriers and enhancing EDI, and work with sites to conduct trials in ways that increase participation of under-represented populations; (3) trial sponsors, researchers, and sites should form long-standing partnerships with patients, patient advocacy groups, and community leaders and groups; (4) anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving EDI; (5) research stakeholders should invest in programs and policies that increase EDI in trials and in the research workforce; and (6) research stakeholders should collect and publish aggregate data on racial and ethnic diversity of trial participants when reporting results of trials, programs, and interventions to increase EDI. The recommendations are intended to serve as a guide for the research community to improve participation rates among people from racial and ethnic minority populations historically under-represented in cancer clinical trials. ASCO and ACCC will work at all levels to advance the recommendations in this publication. (C) 2022 by American Society of Clinical Oncology